Pemvidutide

Pemvidutide is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research[1].

Research Areas >> Metabolic Disease

Pemvidutide (subcutaneous injection; 5 or 10 nmol/kg; once daily; 12 w) treatment improves NASH (nonalcoholic steatohepatitis) outcomes in vivo[1]. Animal Model: C57BL6/J mice (with biopsy-confirmed NAS score after 29 weeks on a HFFC diet)[1] Dosage: 5 or 10 nmol/kg Administration: Subcutaneous injection; 5 or 10 nmol/kg; once daily; 12 weeks Result: Lowered hepatic lipids, liver weight, biomarkers of liver injury (plasma ALT and AST), the inflammation marker galactin-3, the fibrosis marker Col1a1, and the NAS score.